It's never just about "technical" feasibility. #sts101
It's about the "deciding," "we" (see @maxliboiron.bsky.social on there is no such thing as we), "willing," and the assumption that brightness should be added at all.
#TransformingNight 🛰
It's about the "deciding," "we" (see @maxliboiron.bsky.social on there is no such thing as we), "willing," and the assumption that brightness should be added at all.
#TransformingNight 🛰
That’s a useful reminder that a space system can be technically feasible and still fail the human-environment test. The measurement is the easy part; deciding what brightness we are willing to add to a shared sky is the engineering constraint.
September 17, 2026 at 10:42 AM
It's never just about "technical" feasibility. #sts101
It's about the "deciding," "we" (see @maxliboiron.bsky.social on there is no such thing as we), "willing," and the assumption that brightness should be added at all.
#TransformingNight 🛰
It's about the "deciding," "we" (see @maxliboiron.bsky.social on there is no such thing as we), "willing," and the assumption that brightness should be added at all.
#TransformingNight 🛰
심혈관 관련 금기 사항은 여전히 중요하며, 보험 정책이 접근성에 영향을 미칠 수 있습니다. 이 약물의 임상적 역할은 임상의들이 투여 방식, DHE의 약리학적 특성, 내약성, 그리고 다른 이용 가능한 비강 내 투여 옵션들과의 상대적 위치를 어떻게 평가하느냐에 따라 결정될 것입니다. 다른 비강 내 치료제와의 비교 유효성 시험 및 실제 임상 환경 연구는 임상 현장에서의 STS101 활용도를 규명하는 데 중요할 것입니다. (🧵 5/5)
May 31, 2026 at 9:42 AM
심혈관 관련 금기 사항은 여전히 중요하며, 보험 정책이 접근성에 영향을 미칠 수 있습니다. 이 약물의 임상적 역할은 임상의들이 투여 방식, DHE의 약리학적 특성, 내약성, 그리고 다른 이용 가능한 비강 내 투여 옵션들과의 상대적 위치를 어떻게 평가하느냐에 따라 결정될 것입니다. 다른 비강 내 치료제와의 비교 유효성 시험 및 실제 임상 환경 연구는 임상 현장에서의 STS101 활용도를 규명하는 데 중요할 것입니다. (🧵 5/5)
전문가 의견: STS101은 기존의 액상 비강 내 DHE에 비해 흡수율이 더 일관되고 약동학적 변동성이 낮은 비강 내 DHE입니다. 실제로, 이 약물은 비경구적 응급 치료 옵션이 필요한 환자, 특히 주사 요법을 피하고자 하는 환자나 위장관 동반 질환이 있거나 트립탄 또는 게판트 계열 약물에 대한 반응이 불충분한 환자에게 유용할 수 있습니다. (🧵 4/5)
May 31, 2026 at 9:42 AM
전문가 의견: STS101은 기존의 액상 비강 내 DHE에 비해 흡수율이 더 일관되고 약동학적 변동성이 낮은 비강 내 DHE입니다. 실제로, 이 약물은 비경구적 응급 치료 옵션이 필요한 환자, 특히 주사 요법을 피하고자 하는 환자나 위장관 동반 질환이 있거나 트립탄 또는 게판트 계열 약물에 대한 반응이 불충분한 환자에게 유용할 수 있습니다. (🧵 4/5)
적격 자료에는 STS101의 제형, 약동학, 효능, 안전성 및/또는 규제 개발과 관련된 영문 임상 연구, 임상시험 등록 기록, 규제 문서 및 관련 학회 초록이 포함되었습니다. 1상 약동학 시험, 3상 EMERGE 및 SUMMIT 무작위 대조 시험, 그리고 ASCEND 장기 안전성 연구의 데이터가 논의된다. (🧵 3/5)
May 31, 2026 at 9:42 AM
적격 자료에는 STS101의 제형, 약동학, 효능, 안전성 및/또는 규제 개발과 관련된 영문 임상 연구, 임상시험 등록 기록, 규제 문서 및 관련 학회 초록이 포함되었습니다. 1상 약동학 시험, 3상 EMERGE 및 SUMMIT 무작위 대조 시험, 그리고 ASCEND 장기 안전성 연구의 데이터가 논의된다. (🧵 3/5)
다루는 내용: 본 프로필은 급성 편두통 치료를 위한 비경구용 DHE 옵션으로서 STS101의 임상적 활용을 평가하며, 그 제형 설계, 기기 특성, 약동학, 임상적 효능 및 안전성이 실제 진료 현장에서 의미 있는 역할을 뒷받침하는지 평가한다. 'STS101', '디하이드로에르고타민', '편두통', '비강 내 분말'이라는 키워드를 사용하여 데이터베이스 개설 시점부터 2025년 10월까지 Pub Med 및 Clinical Trials.gov에서 표적 검색을 수행했습니다. (🧵 2/5)
May 31, 2026 at 9:42 AM
다루는 내용: 본 프로필은 급성 편두통 치료를 위한 비경구용 DHE 옵션으로서 STS101의 임상적 활용을 평가하며, 그 제형 설계, 기기 특성, 약동학, 임상적 효능 및 안전성이 실제 진료 현장에서 의미 있는 역할을 뒷받침하는지 평가한다. 'STS101', '디하이드로에르고타민', '편두통', '비강 내 분말'이라는 키워드를 사용하여 데이터베이스 개설 시점부터 2025년 10월까지 Pub Med 및 Clinical Trials.gov에서 표적 검색을 수행했습니다. (🧵 2/5)
서론: 효과적인 급성 편두통 치료법이 존재함에도 불구하고, 특히 메스꺼움, 구토 또는 위 배출 지연으로 인해 경구 약물의 복용이 어려운 환자들에게는 여전히 중요한 치료 공백이 남아 있습니다. STS101은 급성 편두통 치료를 위한 비경구용 일회용 제형으로 개발된 새로운 디하이드로에르고타민(DHE) 비강 분말 제제입니다. (🧵 1/5)
May 31, 2026 at 9:42 AM
서론: 효과적인 급성 편두통 치료법이 존재함에도 불구하고, 특히 메스꺼움, 구토 또는 위 배출 지연으로 인해 경구 약물의 복용이 어려운 환자들에게는 여전히 중요한 치료 공백이 남아 있습니다. STS101은 급성 편두통 치료를 위한 비경구용 일회용 제형으로 개발된 새로운 디하이드로에르고타민(DHE) 비강 분말 제제입니다. (🧵 1/5)
성인에서 전조 증상이 있거나 없는 급성 편두통의 새로운 치료 옵션으로서의 STS101 비강 분말
▶️ 논문읽기
📚 출처: Expert review of neurotherapeutics
👤 저자: Bradley Ong et al.
📅 날짜: 2026년 05월 30일
🆔 PMID: 42217235
🔗 DOI: 10.1080/14737175.2026.2681528
#편두통논문g/%ED%8E%B8%EB%91%90%ED%86%B5%EB%85%BC%EB%AC%B8" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#편두통논문 #편두통hashtag/%ED%8E%B8%EB%91%90%ED%86%B5" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#편두통 #펍메드hashtag/%ED%8E%8D%EB%A9%94%EB%93%9C" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#펍메드
▶️ 논문읽기
📚 출처: Expert review of neurotherapeutics
👤 저자: Bradley Ong et al.
📅 날짜: 2026년 05월 30일
🆔 PMID: 42217235
🔗 DOI: 10.1080/14737175.2026.2681528
#편두통논문g/%ED%8E%B8%EB%91%90%ED%86%B5%EB%85%BC%EB%AC%B8" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#편두통논문 #편두통hashtag/%ED%8E%B8%EB%91%90%ED%86%B5" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#편두통 #펍메드hashtag/%ED%8E%8D%EB%A9%94%EB%93%9C" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#펍메드
성인에서 전조 증상이 있거나 없는 급성 편두통의 새로운 치료 옵션으로서의 STS101 비강 분말
서론: 효과적인 급성 편두통 치료법이 존재함에도 불구하고, 특히 메스꺼움, 구토 또는 위 배출 지연으로 인해 경구 약물의 복용이 어려운 환자들에게는 여전히 중요한 치료 공백이 남아 있습니다. STS101은 급성 편두통 치료를 위한 비경구용 일회용 제형으로 개발된 새로운 디하이드로에르고타민(DHE) 비강 분말 제제입니다.
다루는 내용: 본 프로필은 급성 편두통 치료를 위한 비경구용 DHE 옵션으로서 STS101의 임상적 활용을 평가하며, 그 제형 설계, 기기 특성, 약동학, 임상적 효능 및 ...
pubmed.ncbi.nlm.nih.gov
May 31, 2026 at 9:42 AM
성인에서 전조 증상이 있거나 없는 급성 편두통의 새로운 치료 옵션으로서의 STS101 비강 분말
▶️ 논문읽기
📚 출처: Expert review of neurotherapeutics
👤 저자: Bradley Ong et al.
📅 날짜: 2026년 05월 30일
🆔 PMID: 42217235
🔗 DOI: 10.1080/14737175.2026.2681528
#편두통논문g/%ED%8E%B8%EB%91%90%ED%86%B5%EB%85%BC%EB%AC%B8" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#편두통논문 #편두통hashtag/%ED%8E%B8%EB%91%90%ED%86%B5" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#편두통 #펍메드hashtag/%ED%8E%8D%EB%A9%94%EB%93%9C" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#펍메드
▶️ 논문읽기
📚 출처: Expert review of neurotherapeutics
👤 저자: Bradley Ong et al.
📅 날짜: 2026년 05월 30일
🆔 PMID: 42217235
🔗 DOI: 10.1080/14737175.2026.2681528
#편두통논문g/%ED%8E%B8%EB%91%90%ED%86%B5%EB%85%BC%EB%AC%B8" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#편두통논문 #편두통hashtag/%ED%8E%B8%EB%91%90%ED%86%B5" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#편두통 #펍메드hashtag/%ED%8E%8D%EB%A9%94%EB%93%9C" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#펍메드
Comparative effectiveness trials with other intranasal therapies and real-world studies will be important for defining STS101's utilization in clinical practice. (🧵 9/9)
May 31, 2026 at 9:41 AM
Comparative effectiveness trials with other intranasal therapies and real-world studies will be important for defining STS101's utilization in clinical practice. (🧵 9/9)
EXPERT OPINION: STS101 is an intranasal DHE with more consistent absorption and lower pharmacokinetic variability than prior liquid intranasal DHE. Indeed, it may be useful for patients who require a non-oral rescue option, (🧵 6/9)
May 31, 2026 at 9:41 AM
EXPERT OPINION: STS101 is an intranasal DHE with more consistent absorption and lower pharmacokinetic variability than prior liquid intranasal DHE. Indeed, it may be useful for patients who require a non-oral rescue option, (🧵 6/9)
'migraine,' and 'intranasal powder.' Eligible sources included English-language clinical studies, trial registry records, regulatory documents, and relevant conference abstracts addressing STS101 formulation, pharmacokinetics, efficacy, safety, and/or regulatory development. (🧵 4/9)
May 31, 2026 at 9:41 AM
'migraine,' and 'intranasal powder.' Eligible sources included English-language clinical studies, trial registry records, regulatory documents, and relevant conference abstracts addressing STS101 formulation, pharmacokinetics, efficacy, safety, and/or regulatory development. (🧵 4/9)
design, device characteristics, pharmacokinetics, clinical efficacy, and safety support a meaningful role in practice. A targeted Pub Med and Clinical Trials.gov search was performed from database inception throughout October 2025 using the keywords 'STS101,' 'dihydroergotamine,' (🧵 3/9)
May 31, 2026 at 9:41 AM
design, device characteristics, pharmacokinetics, clinical efficacy, and safety support a meaningful role in practice. A targeted Pub Med and Clinical Trials.gov search was performed from database inception throughout October 2025 using the keywords 'STS101,' 'dihydroergotamine,' (🧵 3/9)
STS101 is a novel dihydroergotamine (DHE) nasal powder developed as a non-oral, single-use option for acute migraine treatment.
AREAS COVERED: This profile evaluates the clinical use of STS101 as a non-oral DHE option for acute migraine and evaluates whether its formulation (🧵 2/9)
AREAS COVERED: This profile evaluates the clinical use of STS101 as a non-oral DHE option for acute migraine and evaluates whether its formulation (🧵 2/9)
May 31, 2026 at 9:41 AM
STS101 is a novel dihydroergotamine (DHE) nasal powder developed as a non-oral, single-use option for acute migraine treatment.
AREAS COVERED: This profile evaluates the clinical use of STS101 as a non-oral DHE option for acute migraine and evaluates whether its formulation (🧵 2/9)
AREAS COVERED: This profile evaluates the clinical use of STS101 as a non-oral DHE option for acute migraine and evaluates whether its formulation (🧵 2/9)
STS101 nasal powder as a New treatment option for acute migraine with or without aura in adults
▶️ Read Full Paper
📚 Source: Expert review of neurotherapeutics
👤 Creator: Bradley Ong et al.
📅 Date: 2026-05-30
#MigrainePapertag/MigrainePaper" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MigrainePaper #Migraine/hashtag/Migraine" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Migraine #PubMed="/hashtag/PubMed" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#PubMed
▶️ Read Full Paper
📚 Source: Expert review of neurotherapeutics
👤 Creator: Bradley Ong et al.
📅 Date: 2026-05-30
#MigrainePapertag/MigrainePaper" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MigrainePaper #Migraine/hashtag/Migraine" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Migraine #PubMed="/hashtag/PubMed" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#PubMed
STS101 nasal powder as a New treatment option for acute migraine with or without aura in adults
INTRODUCTION: Although effective acute migraine therapies exist, important gaps remain, particularly for patients whose nausea, vomiting, or delayed gastric emptying make oral medications unreliable. STS101 is a novel dihydroergotamine (DHE) nasal powder developed as a non-ora...
pubmed.ncbi.nlm.nih.gov
May 31, 2026 at 9:41 AM
STS101 nasal powder as a New treatment option for acute migraine with or without aura in adults
▶️ Read Full Paper
📚 Source: Expert review of neurotherapeutics
👤 Creator: Bradley Ong et al.
📅 Date: 2026-05-30
#MigrainePapertag/MigrainePaper" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MigrainePaper #Migraine/hashtag/Migraine" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Migraine #PubMed="/hashtag/PubMed" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#PubMed
▶️ Read Full Paper
📚 Source: Expert review of neurotherapeutics
👤 Creator: Bradley Ong et al.
📅 Date: 2026-05-30
#MigrainePapertag/MigrainePaper" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MigrainePaper #Migraine/hashtag/Migraine" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Migraine #PubMed="/hashtag/PubMed" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#PubMed
Our STS Türkiye Winter School program announced! (January 12-15, 2026)
STS Turkey Science, Technology, and Society Winter School 2026: STS101: Introduction to Science and Technology Studies Location: Ministry of Youth and Sports Facility, Gölbaşı, Ankara Organizers: Şafak Kılıçtepe, Gülizar…
STS Turkey Science, Technology, and Society Winter School 2026: STS101: Introduction to Science and Technology Studies Location: Ministry of Youth and Sports Facility, Gölbaşı, Ankara Organizers: Şafak Kılıçtepe, Gülizar…
Our STS Türkiye Winter School program announced! (January 12-15, 2026)
STS Turkey Science, Technology, and Society Winter School 2026: STS101: Introduction to Science and Technology Studies Location: Ministry of Youth and Sports Facility, Gölbaşı, Ankara Organizers: Şafak Kılıçtepe, Gülizar Karahan Balya, Arsev Umur Aydınoğlu, Melike Şahinol, Emine Öncüler Yayalar, Erkan Saka, İskender Gökalp The STS Turkey Science and Technology Studies (STS Turkey) Research Network continues its work with the aim of increasing the visibility and prevalence of the field by promoting research and educational activities in the field of Science and Technology Studies in our country.
erkansaka.net
December 21, 2025 at 8:09 AM
Our STS Türkiye Winter School program announced! (January 12-15, 2026)
STS Turkey Science, Technology, and Society Winter School 2026: STS101: Introduction to Science and Technology Studies Location: Ministry of Youth and Sports Facility, Gölbaşı, Ankara Organizers: Şafak Kılıçtepe, Gülizar…
STS Turkey Science, Technology, and Society Winter School 2026: STS101: Introduction to Science and Technology Studies Location: Ministry of Youth and Sports Facility, Gölbaşı, Ankara Organizers: Şafak Kılıçtepe, Gülizar…
STS Türkiye Bilim, Teknoloji ve Toplum Kış Okulu 2026
STS Türkiye Bilim, Teknoloji ve Toplum Kış Okulu 2026: STS101: Bilim ve Teknoloji Çalışmalarına Giriş Yer: Gençlik ve Spor Bakanlığı Tesisi, Gölbaşı, Ankara Düzenleyenler: Şafak Kılıçtepe, Gülizar Karahan Balya, Arsev Umur Aydınoğlu, Melike…
STS Türkiye Bilim, Teknoloji ve Toplum Kış Okulu 2026: STS101: Bilim ve Teknoloji Çalışmalarına Giriş Yer: Gençlik ve Spor Bakanlığı Tesisi, Gölbaşı, Ankara Düzenleyenler: Şafak Kılıçtepe, Gülizar Karahan Balya, Arsev Umur Aydınoğlu, Melike…
STS Türkiye Bilim, Teknoloji ve Toplum Kış Okulu 2026
STS Türkiye Bilim, Teknoloji ve Toplum Kış Okulu 2026: STS101: Bilim ve Teknoloji Çalışmalarına Giriş Yer: Gençlik ve Spor Bakanlığı Tesisi, Gölbaşı, Ankara Düzenleyenler: Şafak Kılıçtepe, Gülizar Karahan Balya, Arsev Umur Aydınoğlu, Melike Şahinol, Emine Öncüler Yayalar, Erkan Saka, İskender Gökalp STS Türkiye Bilim ve Teknoloji Çalışmaları (STS Türkiye) Araştırma Ağı, ülkemizde Bilim ve Teknoloji Çalışmaları alanında araştırma ve eğitim faaliyetlerini teşvik ederek alanın görünürlüğünü ve yaygınlığını artırmak amacıyla çalışmalarına devam etmektedir.
sosyalkafa.net
December 20, 2025 at 8:07 PM
STS Türkiye Bilim, Teknoloji ve Toplum Kış Okulu 2026
STS Türkiye Bilim, Teknoloji ve Toplum Kış Okulu 2026: STS101: Bilim ve Teknoloji Çalışmalarına Giriş Yer: Gençlik ve Spor Bakanlığı Tesisi, Gölbaşı, Ankara Düzenleyenler: Şafak Kılıçtepe, Gülizar Karahan Balya, Arsev Umur Aydınoğlu, Melike…
STS Türkiye Bilim, Teknoloji ve Toplum Kış Okulu 2026: STS101: Bilim ve Teknoloji Çalışmalarına Giriş Yer: Gençlik ve Spor Bakanlığı Tesisi, Gölbaşı, Ankara Düzenleyenler: Şafak Kılıçtepe, Gülizar Karahan Balya, Arsev Umur Aydınoğlu, Melike…
Satsuma Pharmaceuticals Reports Positive Outcomes for STS101 Use in Migraine Treatment#United_States#Durham#Satsuma_Pharmaceuticals#STS101#ATZUMI
Satsuma Pharmaceuticals Reports Positive Outcomes for STS101 Use in Migraine Treatment
Satsuma Pharmaceuticals shares findings from its ASCEND study, revealing high satisfaction and rapid pain relief using STS101 for migraines, enhancing treatment options for patients.
third-news.com
November 5, 2025 at 1:35 PM
Satsuma Pharmaceuticals Reports Positive Outcomes for STS101 Use in Migraine Treatment#United_States#Durham#Satsuma_Pharmaceuticals#STS101#ATZUMI
#STSA Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache
https://www.stocktitan.net/news/STSA/satsuma-pharmaceuticals-and-snbl-announce-publication-of-impression-zjwa8thohms1.html
https://www.stocktitan.net/news/STSA/satsuma-pharmaceuticals-and-snbl-announce-publication-of-impression-zjwa8thohms1.html
Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache
Satsuma Pharmaceuticals (NASDAQ:STSA) announced publication (Nov 5, 2025) of patient impression and use data for STS101/Atzumi from the pivotal Phase 3 ASCEND study.Key facts: ASCEND enrolled 482 patients, 446 received at least one dose, and subjects used 10,137 doses for up to 18 months. Participants reported STS101 was easy to use and likely to be used because it worked faster and more consistently than their usual meds. Exploratory efficacy endpoints showed rapid freedom from pain and most bothersome symptoms at 2 hours and sustained benefits through 48 hours.Atzumi is indicated for acute treatment of migraine in adults and carries a boxed warning contraindicating coadministration with strong CYP3A4 inhibitors; common adverse reactions included rhinitis, nausea, altered taste, application site reaction, and dizziness.
www.stocktitan.net
November 5, 2025 at 1:01 PM
#STSA Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache
https://www.stocktitan.net/news/STSA/satsuma-pharmaceuticals-and-snbl-announce-publication-of-impression-zjwa8thohms1.html
https://www.stocktitan.net/news/STSA/satsuma-pharmaceuticals-and-snbl-announce-publication-of-impression-zjwa8thohms1.html
🎧🎙️ A special Mind Moments® episode with Stewart Tepper, MD, just dropped! Tune in as we unpack the FDA’s latest #migraine therapy approvals, STS101 and CT-132, and explore what these innovations mean for care, access, and outcomes.
🧠Listen now: www.neurologylive.com/view/special...
🧠Listen now: www.neurologylive.com/view/special...
Special Episode: Breaking Down the FDA’s Latest Migraine Therapy Approvals with Dr. Stewart Tepper
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Stewart Tepper, MD. [LISTEN TIME: 26 minutes]
www.neurologylive.com
July 18, 2025 at 2:26 PM
🎧🎙️ A special Mind Moments® episode with Stewart Tepper, MD, just dropped! Tune in as we unpack the FDA’s latest #migraine therapy approvals, STS101 and CT-132, and explore what these innovations mean for care, access, and outcomes.
🧠Listen now: www.neurologylive.com/view/special...
🧠Listen now: www.neurologylive.com/view/special...
Satsuma Pharmaceuticals Unveils Significant Findings at the AHS 67th Annual Meeting#United_States#Minneapolis#Satsuma_Pharmaceuticals#SNBL#STS101
Satsuma Pharmaceuticals Unveils Significant Findings at the AHS 67th Annual Meeting
Satsuma Pharmaceuticals presents groundbreaking abstracts at the AHS 67th Annual Scientific Meeting in Minneapolis. Major findings on migraine treatment discussed.
third-news.com
June 19, 2025 at 1:36 PM
Satsuma Pharmaceuticals Unveils Significant Findings at the AHS 67th Annual Meeting#United_States#Minneapolis#Satsuma_Pharmaceuticals#SNBL#STS101
Astronomy Picture from 30/05/2004
Astronaut at Work
Source: https://apod.nasa.gov/apod/ap040530.htm<a href="/hashtag/Spacewalk" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Spacewalkp#ISSa#Astronauts#SpaceShuttleAtlantisA#STS101 #NASA0#SpaceExplorationl#JamesVossa#Orbits#EarthFromSpacer#SpaceHistorye#MissionSuccessn#InternationalSpaceStationeStation
Astronaut at Work
Source: https://apod.nasa.gov/apod/ap040530.htm<a href="/hashtag/Spacewalk" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Spacewalkp#ISSa#Astronauts#SpaceShuttleAtlantisA#STS101 #NASA0#SpaceExplorationl#JamesVossa#Orbits#EarthFromSpacer#SpaceHistorye#MissionSuccessn#InternationalSpaceStationeStation
June 1, 2025 at 10:13 PM
Astronomy Picture from 30/05/2004
Astronaut at Work
Source: https://apod.nasa.gov/apod/ap040530.htm<a href="/hashtag/Spacewalk" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Spacewalkp#ISSa#Astronauts#SpaceShuttleAtlantisA#STS101 #NASA0#SpaceExplorationl#JamesVossa#Orbits#EarthFromSpacer#SpaceHistorye#MissionSuccessn#InternationalSpaceStationeStation
Astronaut at Work
Source: https://apod.nasa.gov/apod/ap040530.htm<a href="/hashtag/Spacewalk" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Spacewalkp#ISSa#Astronauts#SpaceShuttleAtlantisA#STS101 #NASA0#SpaceExplorationl#JamesVossa#Orbits#EarthFromSpacer#SpaceHistorye#MissionSuccessn#InternationalSpaceStationeStation
The U.S. Food and Drug Administration (FDA) has approved a 505(b)(2) New Drug Application (NDA) for Atzumi™ (dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi was previously known as STS101.
May 3, 2025 at 12:42 PM
The U.S. Food and Drug Administration (FDA) has approved a 505(b)(2) New Drug Application (NDA) for Atzumi™ (dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi was previously known as STS101.
NEWS: More than a year after it was rejected by the #FDA, #SatsumaPharma's intranasal #migraine therapy Atzumi (formerly STS101) has been given the go-ahead by the agency.
pharmaphorum.com/news/fda-res...
pharmaphorum.com/news/fda-res...
FDA resurrects Satsuma's nasal migraine treatment
More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi has been given the go-ahead by the agency.
pharmaphorum.com
May 2, 2025 at 1:58 PM
NEWS: More than a year after it was rejected by the #FDA, #SatsumaPharma's intranasal #migraine therapy Atzumi (formerly STS101) has been given the go-ahead by the agency.
pharmaphorum.com/news/fda-res...
pharmaphorum.com/news/fda-res...
Feed: "Endpoints News"
By: Max Gelman on Thursday, May 1, 2025
By: Max Gelman on Thursday, May 1, 2025
FDA approves Satsuma's migraine nasal spray after rejection in 2024
Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine with or without aura.
endpts.com
May 1, 2025 at 11:45 PM
Feed: "Endpoints News"
By: Max Gelman on Thursday, May 1, 2025
By: Max Gelman on Thursday, May 1, 2025
A new acute migraine treatment just got FDA approval! A DHE powder for nasal route (with special applicator). H/t @nwayne66.bsky.social for the good news! www.neurologylive.com/view/fda-app...
FDA Approves STS101 Nasal Powder as New Treatment for Acute Migraine
Satsuma’s STS101 nasal powder becomes the first and only DHE nasal powder for the acute treatment of migraine with or without aura in adults.
www.neurologylive.com
May 1, 2025 at 4:52 PM
A new acute migraine treatment just got FDA approval! A DHE powder for nasal route (with special applicator). H/t @nwayne66.bsky.social for the good news! www.neurologylive.com/view/fda-app...